LexaGene’s MiQLab™ System Featured at Three Key Veterinary Tradeshows
September 03 2021 - 7:45AM
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) a
molecular diagnostics company developing automated rapid polymerase
chain reaction (PCR) testing solutions for veterinary diagnostics
and biopharmaceutical manufacturing, is pleased to announce a
three-city tradeshow itinerary for its MiQLab System. Beginning
this September 7th and through September 26th, the MiQLab will be
featured at some of the veterinary industry’s landmark events in
Las Vegas, Nashville, and San Antonio.
Dr. Jack Regan, LexaGene’s Founder and CEO stated, “We’re
gearing up for a busy and productive fall as we prepare for three
of the bigger events in the veterinary marketplace, after a year
where all in-person events were cancelled or held virtually. We
expect MiQLab’s in-person presence will have significant impact in
the veterinary marketplace and look forward to demonstrating how
vet practices will greatly benefit from in-clinic PCR diagnostics.
Our attendance allows us to take a full-on approach with building
brand awareness, exciting potential buyers, and improving our
market reach through our revamped marketing and sales
strategies.”
From September 7-9, LexaGene will exhibit and host a podium
speaking opportunity at this year’s WVC 93rd Annual Conference, a
gathering of veterinary marketplace leaders featuring over 800
continuing education sessions and 400+ exhibitors. Additionally,
Dr. Regan will speak on the topic of “In-Clinic PCR Testing for
Pathogen ID and Antibiotic Resistance Detection.”
Nashville’s 27th International Veterinary Emergency and Critical
Care Conference from September 12-14, hosts some of the nation’s
top emergency and critical care veterinarians who have the greatest
need for rapid in-clinic pathogen testing. Additionally, LexaGene’s
senior scientist, Dr. Eric DiBasio, MSc, PhD, will present a poster
describing a study using LexaGene’s MiQLab Bacterial and AMR Test
for rapid detection of UTI pathogens. These data demonstrate that
LexaGene’s technology compares favorably with traditional culture
and can enable veterinarians to make more timely evidence-based
treatment decisions. Rounding out the month, LexaGene will travel
to San Antonio for the Southwest Veterinary Symposium being held
September 23-26. This four-day symposium is packed with continuing
education, exhibits, and interactive labs. LexaGene will showcase
its MiQLab to one of the largest regional veterinary audiences and
will have a podium opportunity. Dr. Manoj Nair, MVSc, PhD,
LexaGene’s Director of Applications and Assay Development, will
speak on the topic of bringing automated PCR testing for pathogens
inside the veterinary hospital.
In addition to the veterinary conferences, Dr. Regan continues
to participate in strategic investor relations conferences. For a
complete listing of LexaGene’s conferences, please visit
https://lexagene.com/events/
To learn more about LexaGene and the MiQLab System subscribe to
our company updates or follow us on Twitter or LinkedIn.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Chairman
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing, and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab™ system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately two
hours. The unique open-access feature is designed for custom
testing so that end-users can load their own real-time PCR assays
onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Media and Corporate Contact:
Gail Winslow
Director of Marketing
gwinslow@lexagene.com
978.482.6237
Investor Relations Contact:
ir@lexagene.com
800.215.1824
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024